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The increasing understanding of the immune system and the
critical role of antigenic epitopes in eliciting robust immune
responses has led to the development of peptide vaccines.
Peptide-based vaccines or—more technical—epitope ensem-
ble vaccines represent an alternative approach to the discov-
ery of disease-speciﬁc prophylactic and therapeutic vaccines,
distinct from other vaccine moieties, such as attenuated or
killed whole pathogen vaccines, subunit or toxoid vaccines,
and carbohydrate-based vaccines. Epitopes represent the rel-
evant part of the antigen recognized by T and/or B cells,
mediating adaptive immunity. Consequently, the major
potential of epitope vaccine ensembles is that of inducing
desirable T and B cell-mediated immune responses. The risk
of causing pathogenic or oﬀ-target responses with epitope
vaccines is thus much lower than with convectional vaccines
and can, on that basis, be regarded as safer. Epitope ensemble
vaccines are also very versatile and can be formulated as syn-
thetic peptides or encoded as DNA and RNA formulations.
Currently, there are many epitope vaccines under develop-
ment, spanning a wide range of diseases, including chronic
viral infections and therapeutic anticancer vaccines, but as
yet none are available. The case for epitope ensemble vac-
cines is nonetheless compelling, and the research community
remains certain it is only time that separates us from a viable
and deployable vaccine.
Developing a successful peptide-based vaccine involves
identifying disease-speciﬁc epitopes inducing protective
immunity and tackling a number of steps, such as determin-
ing appropriate means of epitope delivery and overcoming
the intrinsically low immunogenicity of isolated epitopes.
Following the success of previous special issues on peptide-
based vaccines and immunotherapeutics, we present a new
edition of the special issue in which we have incorporated
seven original articles and two reviews, addressing various
aspects of peptide-based vaccine design.
The reviews in the issue deal with epitope databases and
epitope prediction. Peptide databases with information on
T and B cell epitopes and peptide binding to MHCmolecules
are important tools for analyzing immune responses, bench-
marking predictive methods, generating new ones, and
developing peptide-based immunotherapeutics [1]. Cur-
rently, there are a number of online resources providing this
type of information [2] but the Immune Epitope Database
(IEDB) is the largest and most comprehensive epitope data-
base. Thus, in this issue, we are pleased to feature a review
by W. Fleri et al., in which the authors describe how the data
are entered and retrieved from IEDB. B and T cell epitopes
can be predicted from the relevant antigens with the help of
bioinformatics tools. In this issue, J. L. Sanchez-Trincado et
al. analyzed aspects of antigen recognition by T and B cells
that are relevant for epitope prediction and provided a sys-
tematic and inclusive review of available tools, paying partic-
ular attention to their foundations. In the review, the authors
also provide arguments on why B cell epitope prediction is
less accurate and practical than T cell prediction and intro-
duce solutions to solve some of the problems associated with
epitope-vaccine design.
The original articles in this special issue include two
papers focusing on computational vaccine design. In one,
A. R. Oany et al. proposed a peptide vaccine candidate for
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shigellosis consisting of four predicted cytotoxic T cell (CTL)
epitopes from the SigA antigen, which is known to be highly
immunogenic. These four candidates are conserved among
Shigella species and provide wide population coverage. In
addition, the authors identiﬁed that MHC II molecules could
also present two of the CTL epitopes and thus stimulate T
helper responses. In the other, J. Alonso-Padilla et al. have
expanded on an emerging strategy that relies on the use of
experimentally deﬁned T-cell epitopes [3] and formulated a
prophylactic epitope vaccine against EBV infection that
includes both T and B cell epitopes. The T cell component
consists of experimentally deﬁned CD8 and CD4 T cell epi-
topes from various EBV antigens that are conserved and
can be presented by a large number of human MHC mole-
cules, while the B cell component includes experimental B
cell epitopes mapping on the ectodomain of EBV envelope
proteins and exhibiting a high degree of ﬂexibility and sol-
vent accessibility.
The experimental articles in the issue range widely. We
have a work byM. Niki et al.which aims to identify appropri-
ate antigens for tuberculosis (TB) vaccines. The study is an
extension of a previous work in which the authors did a
cross-sectional assay in TB patients [4]. Here, the authors
used a diﬀerent cohort and did a longitudinal assay, ﬁnding
immunoglobulin responses to antigens that correlated to sev-
eral clinical parameters. These results provide insights into
the development of a novel TB vaccine inducing protective
humoral immunity.
Dendritic cell- (DC) and peptide-based immunother-
apies often go hand in hand. In this issue, J. Lo et al. investi-
gate on whether DCs unpulsed or pulsed with antigenic
dominant determinants (DD), subdominant determinants
(SD), and ignored determinants (ID) could prevent type 1
diabetes (T1D) in a mouse model. The authors found that
diabetes was signiﬁcantly delayed by DCs pulsed with SD
or ID peptides. Moreover, they also found that Tregs from
DC-treated mice proliferated more actively and showed
enhanced immunosuppressive activities. Overall, this study
demonstrates that DC therapy leads to long-lasting immuno-
modulatory eﬀects in an antigen-dependent manner, provid-
ing support for DC-guided peptide-based interventions for
autoimmune diabetes.
Toxicity is a handicap for vaccine design and, here, A.
Latanova et al. present a work addressing this issue. In the
study, the authors fused a ﬂaviviral leader peptide to reverse
transcriptase (RT), a crucial target of immunotherapy against
drug-resistant HIV-1. This fusion allowed RT secretion and
reduced its toxicity and ability to induce oxidative stress, with
no major eﬀects on its immunogenicity. Subsequently, the
authors proposed the use of leader peptides to increase safety
of RT-based DNA vaccines. Genetic diversity of pathogens
remain also a substantial obstacle for vaccine design. V. S.
Kichatova et al. addressed this subject for human hepatitis
C virus (HCV). These authors characterized the occurrence
of IFN resistance-conferring mutations in HCV isolates cir-
culating in the Russian Federation, identifying that the
spread of viral variants was linked to mutations on HCV-
speciﬁc CTL epitopes in association with the immunogenetic
background of HCV-infected individuals. These results are
useful in identifying those individuals in need of IFN-free
treatments and for developing epitope-based vaccines that
circumvent viral immune escape.
Finally, we include a work by I. Soria et al. showing that
combining viral-speciﬁc B and T cell epitopes onto appropri-
ated structures can increase immunogenicity and enhance
protection. These authors work with foot-and-mouth disease
virus (FMDV), which has a high morbidity in cloven-hoofed
animals, like cattle and swine. In cattle, there are known
FMDV-speciﬁc B and T cell epitopes that could be used for
safer and more eﬀective vaccines. However, immunization
with linear synthetic peptides encompassing the epitopes
has failed to induce protection in cattle. In contrast, in the
study, the authors immunized cattle with a dendrimeric pep-
tide structures consisting of 4 copies of a peptide encompass-
ing a B cell epitope linked through thioether bonds to a single
copy of a CD4 T cell epitope. As a result, I. Soria et al.
obtained that these dendrimeric peptides elicited humoral
and cellular immune responses that conferred partial protec-
tion against heterologous virus challenge.
In conclusion, the articles included in this special issue
examined relevant aspects of peptide-based vaccines, and
we trust that readers shall ﬁnd them both interesting and
motivating.
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